Dr. Triparna Sen is an Associate Professor, in the Department of Oncological Sciences, and the Director of the Lung Cancer PDX Platform at the Icahn School of Medicine at Mount Sinai, New York. The Sen Lab investigates the biology of initiation, progression, and drug resistance of lung cancer to uncover vulnerabilities that can be therapeutically targeted.

Dr. Sen has driven fundamental advances in the understanding and characterization of clinically relevant molecular subsets of lung cancer, like small cell lung cancer (SCLC). Previously, Dr. Sen identified that DNA damage response (DDR) proteins are effective therapeutic targets for small-cell lung cancer treatment and that targeting DDR promotes antitumor immunity through the activation of innate immune signaling. In her recent work, Dr. Sen identified molecular determinants and novel therapeutic targets of lineage plasticity in lung cancer, illuminating novel therapeutic resistance mechanisms and leading to better treatments.

Dr. Sen has received several prestigious awards including- the AAAS Martin and Rose Wachtel Cancer Research Award (2021); 40 under 40 in Cancer- Emerging Leaders Award (2020); AACR Women in Cancer Research Scholar Award; AACR Scholar-in-training Award; Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. Dr. Sen has received independent grant funding from the National Institute of Health (NIH/NCI-R01), the Department of Defense (DoD) Lung Cancer Research Program, the Lung Cancer Research Foundation (LCRF), and The International Association for the Study of Lung Cancer (IASLC). Dr. Sen is a committee member of the IASLC Basic and Translational Science Committee and the Career Development & Fellowship Committee.